CEPI And EU Grant Valneva $41.3M To Enhance Global Reach Of Chikungunya Vaccine IXCHIQ
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®
- Funding will support clinical trials in vulnerable groups, such as children and pregnant women
- Partnership will also support technology transfer to an additional manufacturer to supply IXCHIQ® to Asian LMICs
- IXCHIQ® is already approved for use in adults 18 years of age and older in the U.S., Canada and Europe